Literature DB >> 24708211

Diosgenin does not express estrogenic activity: a uterotrophic assay.

Ivana Medigović1, Nataša Ristić, Jasmina Živanović, Branka Šošić-Jurjević, Branko Filipović, Verica Milošević, Nataša Nestorović.   

Abstract

This study assessed the effects of diosgenin on estrogenic activity using a uterotrophic assay. Immature female rats received diosgenin orally at doses of 200, 100, or 20 mg/kg body mass; and 17α ethynylestradiol at doses of 1 or 0.3 μg/kg, daily, for 3 consecutive days from day 19 to day 21. Controls were distributed among 2 groups: an intact control group and a vehicle control group. Animals were sacrificed 24 h after the last application of diosgenin, estradiol, or vehicle (22nd day of life). Uterine wet weight, stereological and histomorphometrical changes, immunohistochemical expression of estrogen receptor alpha (ERα), progesterone receptor (PR), and the expression of lactoferrin (LF) were examined. Diosgenin did not affect the uterine wet weight, epithelium height, volume densities of endometrium, endometrial epithelia, number of endometrial glands, or histological appearance of vaginal epithelia. ERα, PR, and LF immunostaining intensity were not altered in the animals that received diosgenin. High-potency reference ER agonist 17α-ethynylestradiol induced a significant increase in all of the measured parameters, and as expected, decreased ERα immunostaining intensity. Based on these data, it can be concluded that diosgenin, at doses of 20-200 mg/kg, did not act as an estrogen agonist in the immature rat uterotrophic assay.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24708211     DOI: 10.1139/cjpp-2013-0419

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  4 in total

1.  Effects of soy phytoestrogens on pituitary-ovarian function in middle-aged female rats.

Authors:  Ivana M Medigović; Jasmina B Živanović; Vladimir Z Ajdžanović; Aleksandra L Nikolić-Kokić; Sanja D Stanković; Svetlana L Trifunović; Verica Lj Milošević; Nataša M Nestorović
Journal:  Endocrine       Date:  2015-07-28       Impact factor: 3.633

2.  High-dose diosgenin reduces bone loss in ovariectomized rats via attenuation of the RANKL/OPG ratio.

Authors:  Zhiguo Zhang; Changheng Song; Xiaowei Fu; Meijie Liu; Yan Li; Jinghua Pan; Hong Liu; Shaojun Wang; Lihua Xiang; Gary Guishan Xiao; Dahong Ju
Journal:  Int J Mol Sci       Date:  2014-09-25       Impact factor: 5.923

3.  A circRNA-miRNA-mRNA network plays a role in the protective effect of diosgenin on alveolar bone loss in ovariectomized rats.

Authors:  Zhiguo Zhang; Lifeng Yue; Yuhan Wang; Yanhua Jiang; Lihua Xiang; Yin Cheng; Dahong Ju; Yanjing Chen
Journal:  BMC Complement Med Ther       Date:  2020-07-14

4.  Diosgenin protects against alveolar bone loss in ovariectomized rats via regulating long non-coding RNAs.

Authors:  Zhiguo Zhang; Yanjing Chen; Lihua Xiang; Zhen Wang; Gary Guishan Xiao; Dahong Ju
Journal:  Exp Ther Med       Date:  2018-09-03       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.